Search

Coloplast A-S (Class B)

Închisă

546.2 0.18

Rezumat

Modificarea prețului

24h

Curent

Minim

541.2

Maxim

546.8

Indicatori cheie

By Trading Economics

Venit

-107M

805M

Vânzări

28M

7B

P/E

Medie Sector

33.892

78.892

EPS

3.88

Randament dividend

4.2

Marjă de profit

11.569

Angajați

16,744

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.20%

2.38%

Statistici piață

By TradingEconomics

Capitalizare de piață

-14B

123B

Deschiderea anterioară

546.02

Închiderea anterioară

546.2

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 dec. 2025, 22:03 UTC

Principalele dinamici ale pieței

Mining Stocks Slip Near the End of Stellar Year

29 dec. 2025, 15:57 UTC

Principalele dinamici ale pieței

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dec. 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 dec. 2025, 23:38 UTC

Achiziții, Fuziuni, Preluări

Manus: Will Continue to Operate From Singapore

29 dec. 2025, 23:38 UTC

Achiziții, Fuziuni, Preluări

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dec. 2025, 23:37 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms: Will Integrate Manus Service Into Products

29 dec. 2025, 23:36 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dec. 2025, 23:36 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dec. 2025, 23:35 UTC

Achiziții, Fuziuni, Preluări

Manus to Join Meta Platforms

29 dec. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

Origin: Raise Values Kraken at US$8.65 Billion

29 dec. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dec. 2025, 21:31 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dec. 2025, 21:31 UTC

Achiziții, Fuziuni, Preluări

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

Origin's Kraken Stake to Remain at 22.7%

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

Origin: Additional Interest Offsets Dilution From Raise

29 dec. 2025, 21:30 UTC

Achiziții, Fuziuni, Preluări

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dec. 2025, 21:29 UTC

Achiziții, Fuziuni, Preluări

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dec. 2025, 21:29 UTC

Achiziții, Fuziuni, Preluări

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dec. 2025, 21:29 UTC

Achiziții, Fuziuni, Preluări

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dec. 2025, 21:27 UTC

Achiziții, Fuziuni, Preluări

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dec. 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dec. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dec. 2025, 20:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dec. 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat